These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20332141)

  • 21. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
    Binkley MS; Rauf MS; Milgrom SA; Pinnix CC; Tsang R; Dickinson M; Ng AK; Roberts KB; Gao S; Balogh A; Ricardi U; Levis M; Casulo C; Stolten M; Specht L; Plastaras JP; Wright C; Kelsey CR; Brady JL; Mikhaeel NG; Hoppe BS; Terezakis SA; Picardi M; Della Pepa R; Kirova Y; Akhtar S; Maghfoor I; Koenig JL; Jackson C; Song E; Sehgal S; Advani RH; Natkunam Y; Constine LS; Eich HT; Wirth A; Hoppe RT
    Blood; 2020 Jun; 135(26):2365-2374. PubMed ID: 32211877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
    Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I
    Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.
    Pinczés L; Miltényi Z; Illés Á
    J Cancer Res Clin Oncol; 2018 May; 144(5):935-943. PubMed ID: 29468437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.
    Cheah CY; Mistry HE; Konoplev S; Fowler NH
    Leuk Lymphoma; 2016 Aug; 57(8):1974-6. PubMed ID: 26762971
    [No Abstract]   [Full Text] [Related]  

  • 26. Transition Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma- Our Histopathological and Clinical Experience With Patients With Intermediate Lymphoma.
    Simon Z; Virga B; Pinczés L; Méhes G; Miltényi Z; Barna S; Szabó R; Illés Á
    Pathol Oncol Res; 2021; 27():625529. PubMed ID: 34257590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
    Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
    Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment results of Hodgkin's lymphoma].
    Aleknavicius E; Valuckas KP; Aleknaviciene B; Norkiene L; Smailyte G
    Medicina (Kaunas); 2009; 45(8):615-23. PubMed ID: 19773620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
    Spinner MA; Varma G; Advani RH
    Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
    Hagberg H; Gisselbrecht C;
    Ann Oncol; 2006 May; 17 Suppl 4():iv31-2. PubMed ID: 16702182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
    Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
    Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment--the Pediatric Oncology Group experience.
    Karayalcin G; Behm FG; Gieser PW; Kung F; Weiner M; Tebbi CK; Ferree C; Marcus R; Constine L; Mendenhall NP; Chauvenet A; Murphy SB
    Med Pediatr Oncol; 1997 Dec; 29(6):519-25. PubMed ID: 9324338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma.
    Glass B; Ziepert M; Reiser M; Freund M; Trümper L; Metzner B; Feller A; Loeffler M; Pfreundschuh M; Schmitz N;
    Ann Oncol; 2010 Nov; 21(11):2255-2261. PubMed ID: 20444844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of lymphocyte-predominant Hodgkin lymphoma.
    Engert A
    Ann Oncol; 2008 Jun; 19 Suppl 4():iv45-6. PubMed ID: 18519402
    [No Abstract]   [Full Text] [Related]  

  • 36. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
    Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
    Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents.
    Murphy SB; Morgan ER; Katzenstein HM; Kletzel M
    J Pediatr Hematol Oncol; 2003 Sep; 25(9):684-7. PubMed ID: 12972802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group.
    Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO;
    Leuk Lymphoma; 2003 Nov; 44(11):1903-10. PubMed ID: 14738141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
    Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C
    Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience.
    Eyre TA; Gatter K; Collins GP; Hall GW; Watson C; Hatton CS
    Am J Hematol; 2015 Jun; 90(6):E103-10. PubMed ID: 25715900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.